# Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

> **NCT05086094** · — · NO_LONGER_AVAILABLE · sponsor: **Biohaven Pharmaceuticals, Inc.**

## Conditions studied

- Multiple System Atrophy (MSA)

## Interventions

- **DRUG:** BHV3241, verdiperstat

## Key facts

- **NCT ID:** NCT05086094
- **Lead sponsor:** Biohaven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05086094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05086094, "Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05086094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*